Stay updated on Ixazomib Combo in Relapsed/Refractory MM Clinical Trial
Sign up to get notified when there's something new on the Ixazomib Combo in Relapsed/Refractory MM Clinical Trial page.

Latest updates to the Ixazomib Combo in Relapsed/Refractory MM Clinical Trial page
- Check7 days agoChange DetectedA new revision entry v3.7.0 was added to the study record history. The previous v3.6.6 entry was removed, updating the documented version history.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedA new revision entry (v3.6.6) appears in the study record history with updated status notes (e.g., Returned, Quality Control Review Has Not Concluded) and the addition of sections like Adverse Events, Outcome Measures (Results), and Participant Flow; the prior revision (v3.6.5) is removed from the history.SummaryDifference0.9%

- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedNew latest revision v3.6.5 appears in the history, replacing the previous v3.6.4 and signaling an administrative update to the record.SummaryDifference0.1%

- Check49 days agoChange DetectedAdded entries indicate the study record now includes Adverse Events, Baseline Characteristics, Participant Flow, and Outcome Measures (Results), along with the Study Status. The entry also notes that the submission was returned on 2026-07-29 with Quality Control Review not concluded.SummaryDifference0.9%

- Check56 days agoChange DetectedA new revision entry v3.6.4 was added to the study history, and the previous revision v3.6.3 was removed from the visible history list, indicating an update to the record's metadata.SummaryDifference0.1%

- Check78 days agoChange DetectedThe study record history now shows a new revision entry labeled v3.6.3, replacing the previous v3.6.2. This reflects an updated version of the record on ClinicalTrials.gov.SummaryDifference0.1%

Stay in the know with updates to Ixazomib Combo in Relapsed/Refractory MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ixazomib Combo in Relapsed/Refractory MM Clinical Trial page.